Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELVN-002 in HER2 Mutant NSCLC and Solid Tumors
NCT05650879Phase 1Active, not recruiting
- Sponsor
- Enliven Therapeutics
- Start
- Mar 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of elvn-002 in non-small cell lung cancer (NSCLC), breast cancer and solid tumor (5 arms), sponsored by Enliven Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities at 42 days, Incidence of Adverse Events at 24 months and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
elvn-002
03
Conditions
non-small cell lung cancer (NSCLC)breast cancersolid tumor
Beyond the preview
Go deeper on NCT05650879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650879.